BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38756785)

  • 1. Enhancing breast cancer outcomes with machine learning-driven glutamine metabolic reprogramming signature.
    Li X; Li X; Yang B; Sun S; Wang S; Yu F; Wang T
    Front Immunol; 2024; 15():1369289. PubMed ID: 38756785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating PANoptosis insights to enhance breast cancer prognosis and therapeutic decision-making.
    Wang S; Li Z; Hou J; Li X; Ni Q; Wang T
    Front Immunol; 2024; 15():1359204. PubMed ID: 38504988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine-learning developed an iron, copper, and sulfur-metabolism associated signature predicts lung adenocarcinoma prognosis and therapy response.
    Zhang L; Zhang X; Guan M; Zeng J; Yu F; Lai F
    Respir Res; 2024 May; 25(1):206. PubMed ID: 38745285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
    Klimov S; Miligy IM; Gertych A; Jiang Y; Toss MS; Rida P; Ellis IO; Green A; Krishnamurti U; Rakha EA; Aneja R
    Breast Cancer Res; 2019 Jul; 21(1):83. PubMed ID: 31358020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
    Liu Z; Guo C; Dang Q; Wang L; Liu L; Weng S; Xu H; Lu T; Sun Z; Han X
    EBioMedicine; 2022 Jan; 75():103750. PubMed ID: 34922323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
    Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
    Terunuma A; Putluri N; Mishra P; Mathé EA; Dorsey TH; Yi M; Wallace TA; Issaq HJ; Zhou M; Killian JK; Stevenson HS; Karoly ED; Chan K; Samanta S; Prieto D; Hsu TY; Kurley SJ; Putluri V; Sonavane R; Edelman DC; Wulff J; Starks AM; Yang Y; Kittles RA; Yfantis HG; Lee DH; Ioffe OB; Schiff R; Stephens RM; Meltzer PS; Veenstra TD; Westbrook TF; Sreekumar A; Ambs S
    J Clin Invest; 2014 Jan; 124(1):398-412. PubMed ID: 24316975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic gene signature for predicting breast cancer recurrence using transcriptome analysis.
    Feng J; Ren J; Yang Q; Liao L; Cui L; Gong Y; Sun S
    Future Oncol; 2021 Jan; 17(1):71-80. PubMed ID: 33397130
    [No Abstract]   [Full Text] [Related]  

  • 9. Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer.
    Du JX; Chen C; Luo YH; Cai JL; Cai CZ; Xu J; Ni XJ; Zhu W
    Gene; 2020 Dec; 762():144974. PubMed ID: 32707305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers.
    Yu TJ; Ma D; Liu YY; Xiao Y; Gong Y; Jiang YZ; Shao ZM; Hu X; Di GH
    Mol Ther; 2021 Jul; 29(7):2350-2365. PubMed ID: 33677091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses.
    Li J; Qiao H; Wu F; Sun S; Feng C; Li C; Yan W; Lv W; Wu H; Liu M; Chen X; Liu X; Wang W; Cai Y; Zhang Y; Zhou Z; Zhang Y; Zhang S
    Front Immunol; 2022; 13():998140. PubMed ID: 36275774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
    McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
    Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer.
    Li Z; Zheng J; Feng Y; Li Y; Liang Y; Liu Y; Wang X; Yang Q
    Cancer Med; 2021 Nov; 10(21):7877-7892. PubMed ID: 34581026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamine Metabolism Regulators Associated with Cancer Development and the Tumor Microenvironment: A Pan-Cancer Multi-Omics Analysis.
    Zou J; Du K; Li S; Lu L; Mei J; Lin W; Deng M; Wei W; Guo R
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer.
    Pei S; Zhang P; Chen H; Zhao S; Dai Y; Yang L; Kang Y; Zheng M; Xia Y; Xie H
    Front Endocrinol (Lausanne); 2023; 14():1135297. PubMed ID: 36843602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression.
    Simpson NE; Tryndyak VP; Beland FA; Pogribny IP
    Breast Cancer Res Treat; 2012 Jun; 133(3):959-68. PubMed ID: 22101407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of molecular subtypes of breast cancer using BI-RADS features based on a "white box" machine learning approach in a multi-modal imaging setting.
    Wu M; Zhong X; Peng Q; Xu M; Huang S; Yuan J; Ma J; Tan T
    Eur J Radiol; 2019 May; 114():175-184. PubMed ID: 31005170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.